- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 19-11-2025: General Updates
19-11-2025 | 09:07 am
19-11-2025 | 09:07 am
Biocon's subsidiary secured US FDA approval for Tofacitinib Extended-Release Tablets (11mg final, 22mg tentative). This significant development strengthens Biocon's portfolio of vertically integrated, complex drug products, enhancing its market position.
No comments yet. Be the first to comment!